Blog

  • How REALS Is Accelerating Sales and Building Buyer Confidence

    How REALS Is Accelerating Sales and Building Buyer Confidence

    NEW YORK, NY / ACCESS Newswire / September 23, 2025 / Selling real estate has always demanded more than numbers on a page. It’s about making the unseen tangible, particularly helping buyers imagine life in a building that may not yet exist. Traditionally, that task has relied on glossy renderings, architectural models, and carefully worded brochures. But as competition among developers intensifies and buyers become more discerning, those static tools are no longer enough.

    That’s why Reuveni Marketing, one of New York’s premier sales and marketing firms, has turned to REALS, the immersive platform from Simplex 3D that Business Insider recently named the top sales tool in real estate. For President and CEO Shlomo Reuveni, its impact is undeniable. Speaking at The Real Deal NYC 2025, he put it plainly: “I can’t imagine not having a tool like this. To us, the value is huge.”

    From Renderings to Real Experiences

    In pre-construction sales, buyers are often asked to commit to multimillion-dollar investments based on little more than promise. A rendering may capture the elegance of a façade, and a drone video can provide a bird’s-eye view of the block. But these fragments rarely add up to the kind of lived-in perspective that inspires confidence.

    That’s where REALS comes in. The platform offers a layered, interactive experience that moves seamlessly from citywide context to the intimacy of an individual unit. “What you have here is something completely out of the box,” Reuveni explained. “We always try to sell on paper, right, before the building is built. And how do you do that in terms of tools? What do you show? You can show a floor plan. You can show some renderings. And yes, you can show a flyby with a drone. And it’s very pretty. But the type of detail that they go down to here in terms of macro to micro… is priceless.”

    Immersion That Inspires Confidence

    REALS elevates that “macro to micro” journey by allowing buyers to toggle seamlessly between perspectives. They can see a development in the context of the city skyline, zoom into a specific block, and even rotate around a building to understand its orientation. From there, they can step inside units virtually, switching between day and night views, adjusting the weather, and exploring how light interacts with interior spaces.

    Neighborhood exploration is equally robust. Sellers can highlight key selling points, local attractions, and transportation access, allowing prospective buyers to experience not only the apartment itself but also the lifestyle it enables. The result is a buying experience that feels both visceral and informed. The platform transforms what used to be a leap of faith an immersive story buyers can step into.

    Data as a Differentiator

    For sales teams like Reuveni Marketing’s, REALS is about actionable insights. Every buyer interaction, whether they linger on a specific room, mark a preference, or compare different layouts, feeds into analytics that reveal what truly matters to them.

    Those insights power smarter sales strategies. Instead of relying on broad assumptions, brokers can tailor conversations around verified interests, while developers gain visibility into what features drive engagement. In a market where timing and precision often dictate success, these behavioral signals provide a measurable edge.

    Building the Sales Office of the Future

    Reuveni Marketing is currently designing more than one million square feet of new development projects, and REALS has become central to how those projects are presented. The traditional sales office, once lined with printed boards and static models, is being reimagined as an interactive hub where clients can experience a project firsthand.

    Buyers who hesitate can virtually walk through a space, inspect the streetscape, and explore the broader neighborhood, all without stepping outside the sales center. For new development marketing teams, that translates into faster decision-making, stronger pre-sales, and the ability to communicate the vision of a project with unprecedented clarity.

    A New Standard for Real Estate

    For years, selling unbuilt properties has meant bridging a chasm between concept and reality. REALS bridges that gap and changes the expectations altogether. Buyers no longer have to rely on imagination alone, and developers can engage clients with a level of personalization and transparency that accelerates trust.

    With REALS by Simplex 3D, this shift is already reshaping the way projects are brought to market. And as its early adopters realize, what began as a tool is quickly becoming a necessity. REALS enhances the sales process while cementing its position as the new industry standard for real estate sales worldwide.

    REALS
    renana@simplex3d.com
    New York City, New York

    SOURCE: REALS

    View the original press release on ACCESS Newswire

  • Chef Rasmus Munk Joins Global Consortium Turning CO2 Into Tasty Foods

    Chef Rasmus Munk Joins Global Consortium Turning CO2 Into Tasty Foods

    – Spora takes role in international consortium aiming to turn CO₂ into protein enough to feed more than 1 billion people every year

    COPENHAGEN, DK / ACCESS Newswire / September 23, 2025 / Will air-to-table be the next big thing? Alchemist chef Rasmus Munk’s food innovation center Spora plays a key role in a global project to create delicious foods from protein derived from CO₂.

    Converting acetate into protein
    Converting acetate into protein
    Info graphic on the process of converting CO2 to protein.

    “We are extremely proud that two of the world’s largest foundations have chosen us as a partner in this ambitious project with the potential to feed more than a billion people every year,” says Rasmus Munk, voted Best Chef in the World 2024 by The Best Chef Awards.

    Spora joins phase 2 of the global “Acetate to Food” project, funded by the Novo Nordisk Foundation and the Gates Foundation. The consortium of research institutions and private companies is pioneering a new way to turn one of our greatest climate liabilities – CO₂ – into nutritious food.

    The process replaces resource-demanding sugar in fermentation with CO₂-derived acetate, which feeds microorganisms that then produce high-quality protein. “When the consortium began two years ago, food from CO₂ seemed like science fiction. Within the next two years, we expect to see prototypes ready for consumer testing. This shows what is possible when biosolutions bring researchers and companies together,” says Claus Felby, Vice President, Agri-Food, Novo Nordisk Foundation.

    Spora, founded by Rasmus Munk in 2023, has been tasked with making the results taste more like dinner than science. “We face a global food and climate crisis, and we need radical solutions. The technology developed in phase one can reshape how we produce food – and I look forward to turning it into nutritious and above all delicious ingredients for the future,” says Rasmus Munk.

    From Molecules to Meals
    Spora’s role will be to combine culinary creativity with science to design sustainable foods for dinner tables worldwide – while addressing hunger and malnutrition in low-income countries.
    “The goal is to develop delicious, protein-rich everyday foods with a low impact on the planet – and broad appeal, especially for families in the communities that need it the most,” says Mette Johnsen, CEO of Spora.

    Working with local chefs and communities, the project will ensure the new foods not only meet nutritional needs but also honor local flavors and cultures.

    The new phase of the project has been granted €21.7 million and will run for the next two years.
    “This project isn’t just about science. It’s about changing the way we feed the world – and making sure that future food is sustainable, accessible, and irresistibly good,” says Rasmus Munk.

    FACTS

    Phase 2 partners: Topsoe, Novonesis, Orkla Foods, Spora ApS, CORC at Aarhus University, University of Copenhagen (Food Science + Food & Resource Economy), Northwestern University, and Copenhagen Process.

    Funding: €21.7 million (DKK 162.2 million), split evenly between the Gates Foundation and Novo Nordisk Foundation.

    More information: Novo Nordisk Foundation

    High res images:
    https://alchemist.filecamp.com/s/c/0YheoaU5mrPE4hR6

    Contact Information

    Lena Ilkjaer
    Head of Communication
    li@alchemist.dk
    +4531318651

    .

    SOURCE: Spora ApS

    View the original press release on ACCESS Newswire

  • Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans

    Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans

    Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups

    Both of Moderna’s COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today’s top circulating COVID-19 strains

    CAMBRIDGE, MA / ACCESS Newswire / September 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE® (COVID-19 Vaccine, mRNA),which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. The data from an ongoing Phase 4 clinical trial evaluating the safety, tolerability and immunogenicity of the 2025-2026 formula of mNEXSPIKE showed, on average, greater than a 16-fold increase in neutralizing antibodies against the LP.8.1 variant in individuals 12 through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older. These findings follow additional preliminary data that showed the 2025-2026 formula of Spikevax® generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across the same age groups.

    The safety profile of the vaccine was consistent with previous studies. These clinical findings underscore the predictability of preclinical data that supported the recent U.S. Food and Drug Administration approval of the 2025-2026 formula of mNEXSPIKE, which is approved for individuals 12 through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older.

    About Moderna

    Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

    Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

    Spikevax® and mNEXSPIKE® are registered trademarks of Moderna.

    What is mNEXSPIKE® (COVID-19 Vaccine, mRNA) AND SPIKEVAX® (COVID-19 Vaccine, mRNA)?

    mNEXSPIKE is a vaccine to protect against COVID-19. mNEXSPIKE is for people who are:

    • 65 years of age and older, or

    • 12 years through 64 years of age at high risk for severe COVID-19.

    SPIKEVAX is a vaccine to protect against COVID-19. SPIKEVAX is for people who are:

    • 65 years of age and older, or

    • 6 months through 64 years of age at high risk for severe COVID-19.

    Vaccination with mNEXSPIKE or SPIKEVAX may not protect all people who receive the vaccine.

    IMPORTANT SAFETY INFORMATION

    You or your child should not get mNEXSPIKE® or SPIKEVAX® if you had a severe allergic reaction after a previous dose of either mNEXSPIKE, SPIKEVAX, any Moderna COVID-19 vaccine, or to any ingredient in these vaccines.

    What are the risks of mNEXSPIKE and SPIKEVAX?

    There is a very small chance that mNEXSPIKE or SPIKEVAX could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of mNEXSPIKE or SPIKEVAX. For this reason, your healthcare provider may ask you to stay for a short time at the place where you received your vaccine. Signs of a severe allergic reaction can include:

    • Trouble breathing

    • Swelling of your face and throat

    • A fast heartbeat

    • A rash all over your body

    • Dizziness and weakness

    Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received mRNA COVID-19 vaccines. Myocarditis and pericarditis following mRNA COVID-19 vaccines have occurred most commonly in males 12 years through 24 years of age. You should seek medical attention right away if you or your child has any of the following symptoms after receiving mNEXSPIKE or SPIKEVAX, particularly during the 2 weeks after receiving a dose of the vaccine: chest pain, shortness of breath, feelings of having a fast-beating, fluttering, or pounding heart. Additional symptoms in children may include fainting, irritability, poor feeding, lack of energy, vomiting, pain in the abdomen, or cool, pale skin.

    Side effects that have been reported in clinical trials with mNEXSPIKE include:

    • Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm of the injection, swelling (hardness), and redness.

    • General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea, vomiting, and fever

    Side effects that have been reported in clinical trials with SPIKEVAX include:

    • Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm of the injection or in the groin, swelling (hardness), and redness

    • General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea and vomiting, fever, rash, irritability/crying, sleepiness, and loss of appetite.

    • Fainting and febrile seizures (convulsions during a fever) have also been reported

    Tell your vaccination provider about all of your or your child’s medical conditions, including if you or your child:

    • have any allergies

    • had a severe allergic reaction after receiving a previous dose of any COVID-19 vaccine

    • have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)

    • have a fever

    • have a bleeding disorder or are on a blood thinner

    • are immunocompromised or are on a medicine that affects your immune system

    • are pregnant or plan to become pregnant

    • are breastfeeding

    • have received any other COVID-19 vaccine

    • have ever fainted in association with an injection

    These may not be all the possible side effects of mNEXSPIKE and SPIKEVAX. Ask your healthcare provider about any side effects that concern you. You may report side effects to Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or http://vaers.hhs.gov.

    Please click for mNEXSPIKE Full Prescribing Information and Information for Recipients and Caregivers.

    Please click for SPIKEVAX Full Prescribing Information and Information for Recipients and Caregivers.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the ability of Moderna’s COVID vaccines to generate an immune response and to protect against circulating COVID strains; and the safety profile of mNEXSPIKE. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

    Moderna Contacts

    Media:
    Chris Ridley
    Head of Global Media Relations
    +1 617-800-3651
    Chris.Ridley@modernatx.com

    Investors:
    Lavina Talukdar
    Senior Vice President & Head of Investor Relations
    +1 617-209-5834
    Lavina.Talukdar@modernatx.com

    SOURCE: Moderna, Inc.

    View the original press release on ACCESS Newswire

  • MSC Industrial Supply Co. to Webcast Review of Fiscal 2025 Fourth Quarter and Full Year Results

    MSC Industrial Supply Co. to Webcast Review of Fiscal 2025 Fourth Quarter and Full Year Results

    MELVILLE, NY AND DAVIDSON, NC / ACCESS Newswire / September 22, 2025 / MSC INDUSTRIAL SUPPLY CO. (NYSE:MSM), a premier distributor of Metalworking and Maintenance, Repair and Operations (MRO) products and services to industrial customers throughout North America, today announced that the Company’s conference call to review its fiscal year 2025 fourth quarter and full year results, as well as its current operations, will be broadcast online live on Thursday, October 23, 2025 at 8:30 a.m. Eastern Time.

    To access the earnings release, webcast, presentation slides and operational statistics, please visit the Company’s website at: http://investor.mscdirect.com. Alternatively, the conference call can be accessed by dialing 1-888-506-0062 (U.S.) or 1-973-528-0011 (international) and providing the access code 420327.

    An online archive of the broadcast will be available within one hour of the conclusion of the call and remain available until Thursday, November 6, 2025.

    # # #

    Contact Information

    Investors:
    Ryan Mills, CFA
    Head of Investor Relations
    Rmills@mscdirect.com

    Media:
    Leah Kelso
    VP, Communications and Sales Enablement
    Leah.Kelso@mscdirect.com

    About MSC Industrial Supply Co. MSC Industrial Supply Co. (NYSE:MSM) is a leading North American distributor of metalworking and maintenance, repair and operations (MRO) products and services. We help our customers drive greater productivity, profitability and growth with approximately 2.4 million products, inventory management and other supply chain solutions, and deep expertise from more than 80 years of working with customers across industries. Our experienced team of more than 7,000 associates is dedicated to working side by side with our customers to help drive results for their businesses – from keeping operations running efficiently today to continuously rethinking, retooling, and optimizing for a more productive tomorrow. For more information on MSC, please visit mscdirect.com.

    SOURCE: MSC Industrial Direct Co.

    View the original press release on ACCESS Newswire

  • Most RPM & CCM Programs Create More Headaches Than Health

    Most RPM & CCM Programs Create More Headaches Than Health

    Connectivity failures, OS updates, and frustrated patients shouldn’t be your problem. Silent devices, outsourced call centers, and disengaged patients create hidden risks and liability. Addison Care delivers fully integrated Virtual Care – engaging patients, protecting providers, and maximizing Medicare value.

    LAS CRUCES, NM / ACCESS Newswire / September 22, 2025 / Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) are the new frontier of Medicare-supported care – but the market is already crowded with half-baked solutions. For providers, the promise of better outcomes and reimbursement too often turns into a tangle of frustrated patients, overwhelmed staff, and mounting liabilities.

    Caregiver and Patient with Addison

    Consider what most clinics face today:

    • The “dark device on the counter.” Patients are given a quiet vitals device. It sits, collects numbers – when the patient remembers to use it – but does nothing to spark engagement or encourage adherence. Data without behavior change is meaningless.

    • The mobile app/Bluetooth nightmare. Thousands of smartphone variations. Constant operating system updates. Endless Bluetooth failures. Patients end up on the phone, not for care, but for tech support. Clinics and staff get dragged into troubleshooting devices instead of practicing medicine.

    • The outsourced TeleCare gamble. Too many vendors send patient calls overseas or to remote home offices. Picture a health crisis handled in a living room with barking dogs, family distractions, and no supervisor watching. HIPAA risk? High. Patient trust? Gone. Provider liability? Through the roof.

    When patients become frustrated, when support is inconsistent, and when calls land back on the clinic’s desk, it is providers – not the vendors – who absorb the fallout.

    Senior user of Addison Care

    The Addison Difference

    Electronic Caregiver built Addison Care to replace those headaches with a higher standard of Virtual Care. Addison is not a gadget or an app, it is a fully integrated care ecosystem where live, professional TeleCare is at the center, and unlike outsourced vendors, every function – onboarding, technology provisioning, patient support, and TeleCare – is vertically integrated under one roof, so providers gain full transparency and control.

    • Engagement Beyond Data
      Addison is more than a vitals hub and beyond the app. She provides continuous nudges, reminders, and support for treatments, daily routines, and lifestyle goals. Patients benefit from companionship, mood and memory support, cognitive exercises, and real human interaction – all proven to improve outcomes. The Addison 3D interactive care interface is the differentiation and efficacy both providers and patients need.

    • Early Detection & Crisis Prevention
      Through regular wellness checks, interactive surveys, and advanced disclosure methods, Addison helps monitor how patients are responding to treatment in real time, while also working to identify early signs of decline, side effects, or exacerbations – empowering providers to intervene before small issues become crises.

    • Compassionate, Controlled TeleCare
      Every Addison Care patient is supported from U.S.-based operations at Electronic Caregiver’s headquarters. Large teams are divided into smaller “patient pods,” so patients hear familiar voices, build trust, and develop comfort over time. This continuity deepens insight into patient history and improves quality of support. All staff are trained through our proprietary Care Coach TeleCare Curriculum, developed in collaboration with New Mexico State University – setting the benchmark for quality care training.

    • Expert Oversight & Security
      Every call, keystroke, and action is monitored, archived, and reviewed under strict supervision. AI systems assist in quality assurance, while continuous audits and penetration testing keep standards at the highest level. Electronic Caregiver has earned AWS Well-Architected Review certification (awarded to only ~3% of global Amazon enterprise clients), ensuring resilience, security, and scalability.

    • Seamless Provider Integration
      Addison Care integrates directly with athenahealth, serving 160,000 health organizations with minimal administrative burden. Our vertically integrated model means no new staff, no disruption, and no upfront costs – just more engagement and better outcomes for the same Medicare reimbursement.

    Gen X Professional with Addison Care Tablet

    A Higher Standard

    Virtual Care should not turn clinics into tech support desks or expose patients to unmonitored call centers abroad. It should deliver maximum value – stronger adherence, earlier intervention, better health outcomes, and greater peace of mind for patients and providers. Provider RPM and CCM programs, fast becoming the standard of care, should scale to serve the maximum number of care support tasks without disruptions to workflows and with excellence in satisfaction.

    Addison Care sets that higher standard. It is the future of Medicare RPM and CCM – delivering outcomes without the risks.

    About Electronic Caregiver

    Electronic Caregiver®, with primary headquarters in Las Cruces New Mexico, is a leading innovator in Virtual Care solutions. Its flagship Addison Care® platform is the world’s first 3D Virtual Caregiver, designed to transform Remote Patient Monitoring, Chronic Care Management, and patient engagement for providers nationwide.

    Media Contact:
    Travis Luevano
    Director, Digital Marketing
    media@ecg-hq.com
    (575) 649-7808

    SOURCE: Electronic Caregiver, inc.

    View the original press release on ACCESS Newswire

  • Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies

    Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies

    New in vitro results show Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation activity, potentially representing a novel frontier in epigenetic therapy where no existing candidates have shown comparable breadth.

    MIAMI, FLORIDA / ACCESS Newswire / September 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company developing therapies that target the root causes of cancer, aging, and age-related diseases, today announced new in vitro pharmacology results demonstrating that Telomir-1 potently inhibits three members of the KDM5 histone demethylase family.

    Histone demethylases are upstream gene regulators that cancers exploit to silence tumor suppressors and activate inflammatory programs. Blocking these enzymes has long been viewed as scientifically important but clinically challenging, with KDM5 often described as challenging for development

    Why This Matters

    Cancer and aging are driven in part by the silencing of protective genes that regulate cell growth, repair, and survival. When these genes are inactive, cells lose critical defenses, enabling tumors to expand and age-related decline to progress.

    This silencing occurs through two major mechanisms:

    1. Histone demethylases (the switches):

      • Members of the KDM5 family are frequently overactive in cancers. Their role is to erase the “on” marks from tumor suppressor genes. When members of the KDM5 family do this, critical genes that normally stop uncontrolled cell growth, repair damage, or trigger cell death are effectively turned off – leaving cancer cells free to divide and accumulate mutations. KDM5 family members are mainly involved in cell cycle progression, stemness, and cancer drug resistance.

      • Members of the KDM2 and KDM6 families work differently. They remove “off” marks from genes that drive inflammation and cell proliferation. While KDM2 family members are mainly involved in gene repression or silencing, often linked with chromatin remodeling and some anti-cancer effects, the KDM6 family members are known for promoting gene activation which is tightly associated with developmental processes, inflammatory responses, and cancer subtype determination

      • Together, these enzymes push the balance in the wrong direction: shutting down the genes that protect cells while activating the ones that promote disease.

    2. DNA methylation (the locks):

      • After histone changes switch genes off, a second layer of control reinforces the silence through DNA methylation.

      • This process involves adding small chemical tags (methyl groups) directly onto the DNA near gene promoters.

      • When these tags accumulate, the gene is no longer accessible to the cell’s transcription machinery – in effect, the gene is shut down.

      • Importantly, these methylation patterns are copied every time a cell divides, which means the silence is passed on from one generation of cells to the next.

      • In cancer, this permanently disables tumor suppressor genes like CDKN2A and STAT1, removing critical brakes on cell growth and immune defense.

      • In aging, widespread changes in DNA methylation contribute to epigenetic drift – the gradual loss of normal gene regulation that underlies tissue decline and age-related disease.

    Telomir-1 has now demonstrated the potential to reset both layers of control:

    • In the new in vitro studies, Telomir-1 potently inhibited three members of the KDM5 family, blocking the silencing of protective genes and preventing the activation of harmful inflammatory pathways.

    • Telomir-1 previously demonstrated activity across other families of histone demethylases, including UTX (KDM6A), JMJD3 (KDM6B), FBXL10 (KDM2B), and FBXL11 (KDM2A). These enzymes are associated with cancer progression, stemness, immune evasion, and age-related decline. Telomir-1 was also shown to spare broad acetyltransferases such as GCN5L2, which are associated with systemic toxicity when inhibited.

    • In other previously reported in vivo prostate cancer studies, Telomir-1 reduced abnormal DNA methylation and reactivated tumor suppressors such as CDKN2A and STAT1, with greater activity than chemotherapy and rapamycin.

    By acting at both the histone and DNA levels, Telomir-1 is emerging as a first-in-class, broad-spectrum epigenetic reset therapy with the potential to restore fundamental cellular defenses relevant to cancer and aging.

    “This is a breakthrough,” said Erez Aminov, Chief Executive Officer of Telomir. “Telomir-1 is demonstrating the potential to create an entirely new class of treatments aimed at the root biology of cancer, aging, and other serious diseases.”

    “Showing that Telomir-1 can potently inhibit several family members of three types of histone demethylases, known to present drug discovery challenges such as selective targeting, cellular permeability, and context-dependent effects, is highly significant,” added Dr. Itzchak Angel, Chief Scientific Advisor at Telomir. “It suggests a new path for tackling how cancers silence protective genes and how aging erodes cellular defenses.”

    Taken together, Telomir-1 demonstrates an unusually broad impact across both DNA methylation and histone demethylation pathways – the fundamental axes of epigenetic control.

    Advancing Toward the Clinic

    Telomir continues to advance IND-enabling studies and GMP scale-up for Telomir-1, with additional preclinical evaluations ongoing across aggressive cancers and models of aging. The Company expects these findings to support its upcoming IND submission.

    About Telomir Pharmaceuticals

    Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a preclinical-stage biotechnology company developing small-molecule therapies that target the root causes of cancer, aging, and age-related diseases by resetting dysregulated epigenetic programs. The Company’s lead candidate, Telomir-1, is being advanced across oncology and longevity indications based on its differentiated ability to restore tumor suppressors, block undruggable enzymes, and reprogram gene control. For more information, visit www.telomirpharma.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

    Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

    Contact Information

    Helga Moya
    info@telomirpharma.com
    (786) 396-6723

    SOURCE: Telomir Pharmaceuticals, Inc

    View the original press release on ACCESS Newswire

  • Ambience Healthcare Announces Nikhil Buduma as New Chief Executive Officer

    Ambience Healthcare Announces Nikhil Buduma as New Chief Executive Officer

    Co-Founder Mike Ng to take the role of President & Chairman

    SAN FRANCISCO, CA / ACCESS Newswire / September 22, 2025 / Ambience Healthcare, the leading ambient AI platform for documentation, coding, and clinical workflows, today announced that Co-Founder and Chief Scientist Nikhil Buduma will step into the role of Chief Executive Officer. Ambience Co-Founder Mike Ng, who served as CEO since the company’s founding, will shift to the full-time executive role of President and Chairman.

    “I am thrilled for Nikhil to step into the role of CEO,” shared Mike Ng, Ambience Healthcare President and Chairman. “Nikhil is respected as one of the most influential AI leaders in the industry by the nation’s leading health systems and academic medical centers. In my new position, I look forward to focusing on Ambience’s long-term vision and strategy.”

    As CEO, Nikhil will focus on leading day-to-day operations, driving company growth, and product innovation. He will also be responsible for ensuring Ambience continues to deliver transformative impact for clinicians and patients while maintaining the company’s culture of operational excellence and long-term mission alignment.

    Buduma and Ng co-founded Ambience in 2020 with the mission of freeing clinicians from the administrative burden of the EHR and enabling them to deliver the best possible patient care. Buduma, one of the early pioneers in deep learning research, authored Fundamentals of Deep Learning (O’Reilly), the first widely adopted textbook on modern AI. He has been recognized by Becker’s Hospital Review as one of its “Rising Stars: 100 Healthcare Leaders Under 40.”

    “I’m excited to partner with Mike in his new role as we focus on forging the next chapter of Ambience’s growth,” said Nikhil Buduma. “Mike cemented our foundational partnerships with AI research labs, led Ambience’s marquee partnerships with leading health systems, and spearheaded our investments into revenue cycle products. Moving forward, Mike and I will continue to work tirelessly to harness AI to deliver better care, at a lower cost, and with a better experience for everyone.”

    Under Ng’s leadership, Ambience Healthcare has grown into one of the most trusted names in healthcare AI. Since its founding, Ambience:

    • Raised $343 million in funding to accelerate development and deployment of its platform

    • Scaled to a team of more than 200 employees across engineering, clinical, and go-to-market functions

    • Partnered with more than 40 leading healthcare organizations, including Cleveland Clinic, UCSF Health, Houston Methodist, St. Luke’s Health System, Memorial Hermann Health System, Ardent Health, and John Muir Health

    • Achieved a 97.7% Spotlight Report score from KLAS Research in the Ambient AI category

    • Became the first ambient AI technology to expand beyond AI scribing into pre-charting, coding, CDI, and clinical decision support

    About Ambience Healthcare
    Ambience Healthcare is the leading AI platform for documentation, coding, and clinical workflow, built to reduce administrative burden and protect revenue integrity at the point of care. Trusted by top health systems across North America, Ambience’s platform is live across outpatient, emergency, and inpatient settings, supporting more than 100 specialties with real-time, coding-aware documentation. The platform integrates directly with Epic, Oracle Cerner, athenahealth, and other major EHRs. Founded in 2020 by Mike Ng and Nikhil Buduma, Ambience is headquartered in San Francisco and backed by Oak HC/FT, Andreessen Horowitz (a16z), OpenAI Startup Fund, Kleiner Perkins, and other leading investors.

    Media Contact:
    Karina Stabile
    Aria Marketing for Ambience Healthcare
    kstabile@ariamarketing.com
    516-317-5835

    SOURCE: Ambience

    View the original press release on ACCESS Newswire

  • From Stiff Steps to Playful Fetch: The YuMOVE(R) 6-Week Challenge Helps Pets on the Path to More Movement

    From Stiff Steps to Playful Fetch: The YuMOVE(R) 6-Week Challenge Helps Pets on the Path to More Movement

    Vetnique Addresses Joint Health for Dogs with Guaranteed Results

    NAPERVILLE, IL / ACCESS Newswire / September 23, 2025 / Vetnique®, the vet-founded pet health brand behind vet-formulated and vet-recommended pet health solutions that are changing the lives of millions of pets, is stepping up to support joint health with the YuMOVE® 6-Week Challenge a nationwide initiative designed to help pets thrive and educate pet parents on proactive joint care.

    YuMOVE holds the top spot as the most recommended joint supplement brand by vets in the UK and is trusted by thousands of vets worldwide. Its proven efficacy is the result of more than 15 years of research and development behind ActivEase® Green Lipped Mussel (GLM) and the proprietary drying process designed to protect the bioactivity of the mussel, ensuring it works harder and more effectively to soothe occasional stiffness and support joint structure and function in dogs of all ages. YuMOVE is scientifically proven to show visible results in just six weeks* – making it a powerful partner in helping dogs move more freely and joyfully.

    Confident in the product’s effectiveness, Vetnique is challenging pet parents across the country to try the scientifically-proven supplement consistently for six weeks to see improved mobility or a full money-back guarantee.

    “At Vetnique, our mission is to help pets thrive through every stage of life,” said Dr. James Bascharon, DVM, Founder and CEO of Vetnique. “The YuMOVE 6-Week Challenge puts that mission in action by helping pet parents take the first step in promoting their pet’s mobility and joint health support. When our pets can move with more ease, it means more walks together, more games of fetch, and more joyful moments that strengthen that bond every day.”

    Challenge Details and Tracking Your Pet’s Progress

    As part of the YuMOVE 6-Week Challenge, Vetnique released expert tips, tools, and resources to track progress week over week, such as:

    • A downloadable YuMOVE Pawgress Report tracker, which provides pet parents with key indicators to help identify joint health improvements

    • Vet-approved blogs dedicated to improving mobility, movement, and play

    • The Share Your Story Sweepstakes, a chance to enter to win over $1,200 in prizes to support mobility, including toys from Chuckit!®, the go-to brand for fetch and play

    • A discount of 40% off your first purchase of any YuMOVE product on Vetnique.com

    To find out more about the vet-approved resources, special offers on YuMOVE joint supplements, and to begin the YuMOVE 6-Week Challenge, visit Vetnique.com.

    *In vivo, double-blind, placebo-controlled, objectively measured canine clinical study by a leading UK Veterinary College (Excluding YuMOVE Joint Care for Young Dogs)

    Media Contact

    Mike Wehner – mike@notablypr.com

    About Vetnique

    Vetnique is a one-of-a-kind, global pet wellness company committed to helping your one-of-a-kind pets thrive with vet-recommended health care solutions. Founded by a veterinarian, supported by a team of passionate pet lovers, and recommended by over 100,000 veterinarians worldwide, Vetnique has evolved into one of the fastest-growing, omnichannel pet brands in North America. Vetnique combines scientifically backed research with over a decade of experience to ensure every product is designed to meet the unique needs of pets. Uniquely Vet Founded, Vet Formulated, and Vet Recommended. Learn more about Vetnique at Vetnique.com.

    SOURCE: Vetnique

    View the original press release on ACCESS Newswire

  • Northeastern University Expands Partnership With iFOLIO to Power Global Donor Stewardship

    Northeastern University Expands Partnership With iFOLIO to Power Global Donor Stewardship

    From paper to digital: 1 Million immersive donor reports powered by iFOLIO.

    ATLANTA, GA / ACCESS Newswire / September 18, 2025 / Northeastern University, home to one of the fastest-growing alumni networks in higher education, expanded its partnership with iFOLIO to digitally transform donor stewardship at scale across all 13 global campuses. This initiative delivers immersive digital content to deepen donor relationships and elevate engagement worldwide.

    iFOLIO x Northeastern University
    iFOLIO x Northeastern University

    “As donor expectations evolve, stewardship is no longer about static PDFs or paper mailings that may never be opened,” said Jean Marie Richardson, CEO of iFOLIO. “Today’s donors expect curated, personalized experiences with engaging digital content they can access instantly. iFOLIO not only delivers that elevated experience, but also provides real-time insight into when communications are delivered, opened, and acted on. Northeastern is pioneering this new model across its global network, setting a higher standard for philanthropy and donor engagement in higher education.”

    iFOLIO’s Impact in Higher Education includes supporting more than $4 billion in philanthropic contributions across 23 universities.

    Through iFOLIO, Northeastern has already transformed donor communications from static documents into dynamic, personalized reports featuring videos, animations, flipping panes about impact, links to more stories, and real-time analytics. This approach has not only streamlined operations but also provided measurable insights to guide future donor strategy.

    This Northeastern initiative powers:

    • 1 million+ digital communications annually, including endowment reports, impact reports, annual reports, dean’s reports, and more

    • Custom CRM integration to automate data flows and unlock actionable insights.

    • Scaling personalized stewardship across 13 global campuses with interactive digital storytelling.

    With this expansion, Northeastern reinforces its role as a leader in higher education innovation – demonstrating how technology can be harnessed to scale stewardship, personalize donor touch points, and strengthen relationships worldwide.

    About iFOLIO
    iFOLIO Marketing Cloud is the most robust enterprise platform for digital marketing, productivity, and innovation. Trusted by over 5,000 clients, powering over 3 million pages and sites, and viewed in all 50 U.S. states and 120 countries, iFOLIO enables organizations to deliver immersive content and real-time engagement insights for growth. SOC 2 certified and based in Atlanta, Georgia, iFOLIO provides an all-in-one digital marketing solution with collaborative design tools, automation, and patented data intelligence.
    For more information, visit: www.ifoliocloud.com

    Contact Information

    Rachel Carlson
    Marketing & Design Manager
    rachel.carlson@ifoliocloud.com
    470-223-4818

    .

    SOURCE: iFOLIO

    View the original press release on ACCESS Newswire

  • Boomerang Ventures Invests $1M in Sonara Health to Scale Hybrid Methadone Care Nationwide

    Boomerang Ventures Invests $1M in Sonara Health to Scale Hybrid Methadone Care Nationwide

    Sonara Health is a Portfolio Company of Boomerang Ventures

    INDIANAPOLIS, IN / ACCESS Newswire / September 23, 2025 / Boomerang Ventures today announced it has made a $1 million strategic investment in Sonara Health, a Dallas-based health technology company transforming opioid treatment programs (OTPs) through its hybrid care platform. The funding is part of Sonara’s latest investment round, which included leading impact investors Acumen America, Sorenson Impact Foundation, Oakwood Circle Ventures, Royal Street Ventures, and First Trust Capital Partners.

    Sonara Health’s innovative solution combines in-person and virtual tools to modernize methadone treatment delivery for people with opioid use disorder (OUD). At the center of its platform is the Virtual Dosing Window™, which enables patients to securely record take-home methadone doses by scanning a QR code on their bottle and creating a video for clinical review. This approach, combined with their validated clinical measures, greatly reduces the need for daily in-person visits while helping providers improve adherence, retention, and patient trust.

    “Our investment in Sonara is about scale and impact,” said Oscar Moralez, Founder & Managing Partner, Boomerang Ventures. “Sonara’s hybrid model does more than digitize workflows, it connects patients, providers, and care teams with clinically meaningful data at the moment of decision. This capital enables Sonara to expand payer engagement, strengthen clinical decision-support around take-home dosing, and grow tech-enabled medication units so more people can access life-saving treatment with fewer barriers. It’s a clear example of how we back founders who rethink healthcare delivery in ways that improve patient outcomes and system efficiency.”

    Early Outcomes Driving Real-World Impact
    Since launching in late-2022, Sonara Health has already shown measurable results:

    • 4,200+ patients have been supported across more than 50 clinics in 14 states

    • Participants average 14 additionaltake-home doses per month

    • Each patient avoids approximately 28 extra clinic tripsmonthly

    • Payers report an estimated 10.75x ROI, fueled by fewer non-emergency medical transportation needs and patients staying reliably on track with treatment

    “Boomerang Ventures has been a committed, hands-on partner,” said Michael Giles, MD, Founder & CEO, Sonara Health. “Their investment and strategic guidance help us accelerate the tools and partnerships that make hybrid methadone care sustainable, from reimbursement pathways to decision-support that keeps patients safe and engaged. We’re excited to expand access to evidence-based treatment for communities that need it most.”

    The new funding supports Sonara’s continued work to modernize methadone treatment delivery, advance patient-centered care, and expand access through payer engagement, enhanced clinical tools (including take-home dosing and long-term recovery planning), and technology-enabled medication units in high-need areas.

    About Boomerang Ventures

    Founded in 2019, Boomerang Ventures is a venture capital firm focused on early growth-stage connected health technology companies. Leveraging a combination studio and venture fund, Boomerang provides the collaborative direction, deep industry expertise, and continuum of support founders need to take their innovations from ideation to market. Boomerang believes that better patient care begins with identifying and solving the biggest challenges in healthcare. Boomerang Ventures is proudly and strategically based in Indianapolis, where the healthcare and entrepreneurial business climate is a thriving community ripe with opportunities. With a secure niche at the intersection of health technology, studio-fund synchronization, and the Midwest, Boomerang differentiates itself from the competition. Boomerang Ventures is Healthcare Innovation, Reimagined. For more information, visit boomerang.vc.

    About Sonara Health

    Sonara Health is transforming methadone treatment through a hybrid care platform that makes it easier for people with opioid use disorder (OUD) to start and stay in treatment. By combining in-person care with virtual tools, Sonara removes common barriers, like daily clinic travel, that often affect treatment retention. At the core of the platform is Sonara’s patented, tamper-aware medication adherence system, the Virtual Dosing Window™, which enables patients to securely record doses from home while maintaining clinical oversight. The platform also supports remote intake, telecounseling, in-app messaging, and real-time adherence insights, helping care teams stay connected to patients between visits and make more informed clinical decisions. Clinically validated in a peer-reviewed NIH-funded study, Sonara is now used in over 50 locations across 14 states and is helping opioid treatment programs improve retention, build trust with patients, and expand access to life-saving care. For more information, visit sonarahealth.com.

    # # #

    Media Contact:
    Audra Wait, President
    Wait & Co. (on behalf of Boomerang Ventures)
    audra@waitandco.com | 615-504-8812

    SOURCE: Boomerang Ventures

    View the original press release on ACCESS Newswire